Archive | March, 2017

Hot Investor Mandate 1: Family Office Invests in Highly Differentiated Novel Therapeutics, Devices and Diagnostics

9 Mar

A family office has a healthcare focused investment arm based in New York. The firm is interested in global companies, but is currently more focused on the US, Canada, Europe, and Israel regions. The firm makes investments ranging from $5 – $80 million. The firm is open to both leading and co-investing. The firm prefers investing in companies that have demonstrated clinical data and is currently not limited in the number of investments they plan to make this year.

The firm is interested in therapeutics, medical devices, and diagnostics. The firm is agnostic to the types of therapeutics, devices, and diagnostics they look to invest in. The firm is most interested in highly differentiable products that address unmet medical needs.

The firm looks for experienced management teams and depending on the deal, may or may not seek a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: Pharma Firm Looks Worldwide for Treatments for Ultra Rare Diseases

9 Mar

A pharma firm based in the US specializes in treatments for diseases with under 20,000 patients in the USA or EU, and is seeking to in-license novel therapeutics and platforms in this space.

The firm is interested in therapeutic assets that treat severe, rare to ultra-rare diseases with high levels of mortality/morbidity. The firm is interested in assets at any stage, from discovery and early preclinical (i.e. where there may only be an animal model of disease that exists but no therapeutic yet) to marketed products. The firm requires that a treatment be transformative for patient care. While the firm’s primary experience is in antibodies and protein-based drugs, the firm is open to exploring opportunities that utilize other therapeutic modalities such as small molecules, gene therapy and nucleic acids. In addition, the firm is looking for new therapeutic platform technologies, especially those that can enhance the blood brain barrier penetrance of biologics as well as new methods to deliver nucleic acids to cells and target organs.

The firm is open to working with companies anywhere in the world, and has no set requirements for partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: Hong Kong Conglomerate Invests in Brain Diseases, Oncology and Ophthalmology

9 Mar

A multi-disciplinary conglomerate based in Hong Kong continues to diversify its business and growth globally with interests in a diverse range of business partnerships, including life sciences. The for, can and typically takes a long-term approach to such investments, with a focus on early stage life science companies, and syndicates with prominent co-investors to form a global network for sourcing and accessing deals, where the allocation size can be flexible depending on the deal. The firm is actively seeking new opportunities based in the U.S. and China.

Within healthcare, the firm looks at cutting-edge biotech therapeutic technologies across small molecule, biologics, and novel therapies. The group focuses on brain diseases, oncology, and ophthalmology. The group is also interested in drug delivery platforms and genomic diagnostics. In terms of development stages, the group focuses on preclinical to early clinical stage assets that are seeking series A or B financing.

The firm looks for experienced and competent teams with sector expertise and track record of success. The firm prefers opportunities where they have already identified a healthcare-focused lead investor. The firm typically requests board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: China-Based Fund Opportunistically Invests in Medtech, Biotech, Healthcare IT and Diagnostics

9 Mar

A venture capital firm based in Shanghai, China, is managing one fund with committed capital of $140 million. The firm typically makes equity investment into life science companies at various stages. The investment size generally ranges from $10 million to $15 million over the life of an investment. The firm seeks to make 3-5 allocations in the next year. The firm focuses on companies that are based in China and the US.

The firm is currently looking for new investment opportunities in Biotechnology R&D, Therapeutics & Diagnostics, Pharmaceuticals, Medical Devices and Healthcare IT spaces. The firm is very opportunistic in terms of subsectors and indications. The firm is interested in in-licensing products or technologies for development from companies outside of China, such as US-based companies. The firm also seeks to invest in orphan drugs. Prior investments have included medical device companies, diagnostics companies, CRO and distributors. The firm will consider companies in all stages, depending on the opportunity.

The firm seeks to invest in both private and public companies. The firm has no specific requirements for companies’ management team, revenue or EBITDA.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Meet with Asia Pacific Investors at RESI

2 Mar

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

Shaoyu 10*10

A rising number of investors and business delegations from the Asia Pacific region are traveling around the world in search for healthcare innovations. The RESI conference team is pleased to invite a panel of Asia Pacific investors to discuss their investment strategies.

Asia Pacific Investors come in different shape and forms. Private funds are searching for exponential return on investment. Pharmaceutical and research organizations look for a strategic fit with their portfolio. Traditional industry corporations look to expand into healthcare.

As major North American hotbeds are getting crowded with foreign investors in recent years, emerging life science hubs such as Toronto have become attractive destinations for their quality startups in a less competitive scene.

RESI attendees will have a unique opportunity to meet with these groups face-to-face.  The session will feature the following:

Tags: , , , ,

RESI on MaRS Panel Announcement: Corporate Venture Capital

2 Mar

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

Large corporations, especially in the pharmaceutical/biotech world, play a very important role in anchoring an innovation ecosystem. The most notable activity of these corporations is perhaps their role as an investor in and buyer of innovation, an exit partner; however, attracting and concentrating talent, providing access to resources and experts are also vital elements of a healthy entrepreneurial community that big pharma brings with its presence. Corporate venture funds, which can serve as a vehicle for big pharma to make riskier/earlier investments, continue to find their way into more and more biotech venture rounds every year.

Toronto, looking to ramp up commercialization of its world-class research and put its name on the map as a life science powerhouse, will host the RESI conference for the second time and welcome a panel of Corporate Venture investors. This increasingly important investor class will discuss trends in the space, their current interests and how entrepreneurs can best prepare to pitch to and work with a group like theirs.

Moderated by John Gustofson, Senior Director, Abbvie Ventures, this panel will feature:

By registering for RESI on MaRS, you’ll be able to listen to the Corporate Venture Capital panel live and learn how to position yourself to work with this type of group as well as interact with the a range of investors and entrepreneurs and experience numerous opportunities to expand your network in the life sciences.

Tags: , , , , , , ,

Hot Investor Mandate 1: China Bank Partners With VC for $500 Million North America Life Science Fund

2 Mar

A venture capital firm based Canada has jointly established a $500M fund with a leading Chinese investment bank. The firm usually makes initial investments in the range of $5M-$10M with additional capital reserved for follow-on investments, but is capable of making smaller or larger investments. The firm primarily makes straight equity investments, but may consider convertible notes for smaller/earlier rounds. On occasion, public companies may be considered for investment. The firm is open to opportunities globally and will lead rounds as well as co-invest in a syndicate, and is able to act quickly when an opportunity presents itself.

The firm’s focus is in health sciences, including therapeutics, devices, diagnostics and health IT.  Generally, the firm focuses on assets with clinical data and will invest in up unto Ph. III. The firm will evaluate pre-clinical assets pending there is a strong scientific rationale, and tends to prioritize platform technologies for early-stage assets. As for medical device companies, the firm prefers to see products with clinical data.

The firm prefers to work with experienced management teams, but will consider first time entrepreneurs as well. The firm typically seeks a board seat along with investment and in addition to capital, seeks to add value through developmental, infrastructure and expertise support, as needed, through the firm’s global network. The firm’s approach is to establish long-term relationships with target companies, with a view to enable and strengthen management to realize the full potential and value of the technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

← Older Entries
Newer Entries →